



POSTER LISTINGS*

PROFFERED ABSTRACTS	Page 1
POSTER SESSION A	Page 3
POSTER SESSION B	Page 7
POSTER SESSION C	Page 12

**As of November 7, 2025*

Proffered Abstracts

PR001, A024 Risk prediction modeling for colorectal adenomas in persons under age 50: a risk-stratified approach to early onset colorectal cancer prevention. Shria Kumar, University of Miami / Sylvester Comprehensive Cancer Center, Miami, FL, United States

PR002, A031 Clinical, pathological, and molecular differences in early- and late-onset colorectal cancer: Results from a multicenter study. Nastaran D. Riahi Dehkordi, Universal Diagnostics d.o.o., Ljubljana, Slovenia

PR003, C016 Exploring the exposome impact in early-onset colon and rectal cancer using methylation scores. Silvana C.E. Maas, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

PR004, C015 Mutational signature profiling identifies a distinct subgroup of early-onset colorectal cancer associated with younger age at diagnosis, recent birth year, and specific genomic features. Daniel D. Buchanan, University of Melbourne, Parkville, VIC, Australia

PR005, B009 Uncovering the Etiology of Early-Onset Gastric Cancer in Latinos Through Germline and Tumor Genomic Profiling. Luis G. Carvajal-Carmona, University of California, Davis, Davis, CA, United States

PR006, B030 Temporal Trends in the Incidence of Obesity-Associated Cancers in Puerto Rico, 2000–2022: Disproportionate Increases Among Younger Adults. Carola T. Sánchez-Díaz, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto RicoC029

PR007, C029 Tumor-adjacent visceral adipose tissue displays an altered transcriptomic landscape in early-onset colorectal cancer patients: Results from the ColoCare Study. Victoria M. Bandera, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, United States

PR008, B032 Incidence of early onset colorectal, kidney, uterine, and pancreatic cancer by county-level obesity prevalence in the U.S., 2010-2022. Meredith Shiels, National Cancer Institute, Rockville, MD, United States

PR009, A005 Bugs in Space: Spatial Analysis of the Immune-Microbial Axis in Rectal Cancer Reveals a Unique Interface in Young-Onset Rectal Cancers. Ryan Morgan, MD Anderson Cancer Center, Houston, TX, United States

PR010, C019 Early-life penicillin blooms colibactin-positive Escherichia coli and drives DNA damage and tumorigenesis. Max R. Van Belkum, Vanderbilt University School of Medicine, Nashville, TN, United States

PR011, C002 Early-onset colorectal cancer is characterized by transcriptional changes indicating increased epithelial-mesenchymal transition and metastatic potential. Ana C. Anderson, Gene Lay Institute of Immunology and Inflammation, Mass General Brigham, Harvard Medical School, Boston, MA, United States

PR012, C033 Transcriptomic and pathway analyses patterns in early-onset and late-onset microsatellite stable colorectal cancer: Results from the ORIEN Network. Sheetal Hardikar, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States

PR013, A020 Distinct Oral Bacterial Signatures in Rectal Cancer Tumors Associated with Age of Onset and Treatment Response. Nadim J. Ajami, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

PR014, A032 FIT for red flag signs and symptoms of early onset colorectal cancer: low value or viable diagnostic tool? Daniel Sabater Minarim, University of California San Diego, La Jolla, CA, United States

PR015, C022 Multidimensional assessment of toxicities and survivorship among people with early-onset colorectal cancer – Results from the ColoCare Study. Jane C. Figueiredo, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, United States

PR016, B023 Supplement And Medication Use in Early-Onset Colorectal Cancer: An Analysis of the Ohio Colorectal Cancer Prevention Initiative. Holli A. Loomans-Kropp, The Ohio State University, Columbus, OH, United States

Poster Session A

Wednesday, December 10, 2025, 7:30-9:00 p.m.

A001 Unravelling the molecular structural and functional roles of the homologous Mouse double minute RINGs interface for targeted anticancer design. Adeniyi T. Adewumi, University of South Africa, Roodepoort, South Africa

A002 Real-world clinicogenomic comparison of early- and average-onset gastric cancer. Mautin Barry-Hundeyin, University of Kentucky, Lexington, KY, United States

A003 Unfinished Stories: Consequences of Melanoma Clinical Trial Discontinuation and Non-Publication. Hadeer Hafez, Faculty of medicine, October 6th university, october 6th, Egypt

A004 Paid Family Leave as a Cancer Prevention Strategy? The association of state-paid family leave implementation with early-onset breast and endometrial cancer incidence. Erica J. Lee Argov, Columbia University Mailman School of Public Health, New York, NY, United States

A005 Bugs in Space: Spatial Analysis of the Immune-Microbial Axis in Rectal Cancer Reveals a Unique Interface in Young-Onset Rectal Cancers. Ryan Morgan, MD Anderson Cancer Center, Houston, TX, United States

A006 Natural interception of drug resistance in breast cancer: Nanoencapsulation of *Terfezia* extracts enhances doxorubicin sensitivity in early-onset models. Roua A. Nouh, The American University in Cairo, Cairo, CA, Egypt

A007 Calcitonin gene-related peptide (CGRP) and receptor activity-modifying protein 1 (RAMP1) drive tumor cell growth in early-onset human gastric cancer. Pavitha Parathan, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia

A008 Psychosocial Survivorship Gaps in Early-Onset Cancers: Opportunities for Digital Health Research. Manisha Salinas, Mayo Clinic, Jacksonville, FL, United States

A009 Mutation Matters: ATM and BRCA1/2 Shape Divergent Coagulopathy Programs in Pancreatic Cancer. Allen Seylani, UCR, Riverside, CA, United States

A010 Are We Delaying Ovarian Cancer Diagnosis in Young Women?: Sensitivity of CA-125 Thresholds for Early-Onset Ovarian Cancer in Large Cohort. Anna Jo B. Smith, University of Pennsylvania, Philadelphia, PA, United States

A011 Early Onset Cancer Incidence: A Model for the Role of Diagnostic Advances. Ruth D. Etzioni, Fred Hutch Cancer Center, Seattle, WA, United States

A012 A Deep Learning Framework for Predicting Survival in Gastric Cancer: A Comparative Analysis with Traditional Cox Regression. Ahmed M. Badheeb, Hadhramout University College of Medicine, Mukalla, United States

A013 ²²⁵Actinium and tandem ¹⁷⁷Lutetium ²²⁵Actinium - FAPi therapy in medullary thyroid carcinoma. Nitin Gupta, Rajiv Gandhi Cancer Institute & Research Centre, Rohini, New Delhi, , India

A014 Prognostic value of tumor asphericity on initial staging ¹⁸F- FDG PET/CT in patients with breast cancer. Nitin. Gupta, Dr Rajendra Prasad Government medical college and hospital, Kangra, India

A015 Retinoblastoma points to solutions for Early-Onset Cancers. Brenda. Gallie, International Retinoblastoma Consortium, Hospital for Sick Children, Princess Margaret Cancer Centre, Toronto, ON, Canada

A016 Cascade Failure in Lynch Syndrome Diagnosis: A Single-Institution Analysis. Gideon T. Dosunmu, Emory University Health, Atlanta, GA, United States

A017 Equity and the age cutoff problem: Rethinking early detection and screening in Nigeria. Deloraine A. Dennis, National Institute for Cancer Research and Treatment (NICRAT), Abuja, Nigeria

A018 Colorectal cancer screening remains low despite high burden and rising early-onset cases in Puerto Rico, 2016–2021. Vivian Colon-Lopez, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico

A019 Clinical characteristics and outcomes of primary cardiac leiomyosarcoma cases from 2015-2025: A literature review. Taylor C.S. Bailey, Charles R. Drew University School of Medicine and Science College of Medicine, Los Angeles, CA, United States

A020 Distinct Oral Bacterial Signatures in Rectal Cancer Tumors Associated with Age of Onset and Treatment Response. Nadim J. Ajami, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

A021 A human-induced pluripotent stem cell (hiPSC)-derived cardiac spheroids (hiPSC-CSs) platform for individualized cancer drug cardiotoxicity assessment. Chia-Hsien Hsu, National Health Research Institutes, Zhunan, Taiwan (Greater China)

A022 Exploring the association of quantitative fecal immunochemical test (qFIT) with red-flag symptoms of early-onset colorectal cancer. Amy E. Hughes, UT Southwestern Medical Center, Dallas, TX, United States

A023 Cell-Free DNA: A Paradigm Shift in Cancer Diagnostics and Precision Medicine. Mohamed Tharwat. Kamouna, Merit University in Egypt, Sohag, Egypt

A024 Risk prediction modeling for colorectal adenomas in persons under age 50: a risk-stratified approach to early onset colorectal cancer prevention. Shria Kumar, University of Miami / Sylvester Comprehensive Cancer Center, Miami, FL, United States

A025 Accelerated aging as a predictor for early-onset colorectal cancer. Shria Kumar, University of Miami / Sylvester Comprehensive Cancer Center, Miami, FL, United States

A026 Use of recommended diagnostic breast imaging among women under 40 in a community-based registry. Sarah J. Nyante, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

A027 Mode of presentation and symptoms at diagnosis of early- and late-onset colorectal cancer: a large retrospective AI-powered analysis. Emerik Osterlund, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

A028 Exploring exposure to and metabolism of polycyclic aromatic hydrocarbons (PAHs) in patients with cancer predisposition syndromes (CPS): research in progress. Judy Ou, Huntsman Cancer Institute; University of Utah, Salt Lake City, UT, United States

A029 Breast Cancer Screening During Reproductive Years in Women with Germline Pathogenic Variants: Gaps in Counseling and Practice. Laura M. Pacheco-Spann, Mayo Clinic, Jacksonville, FL, United States

A030 The role of liquid biopsies in optimizing early-onset non-small cell lung cancer (NSCLC) cancer screening and detection in underserved populations globally. Nicole Ramlachan, University of Trinidad and Tobago, Valsayn, Trinidad and Tobago

A031 Clinical, pathological, and molecular differences in early- and late-onset colorectal cancer: Results from a multicenter study. Nastaran D. Riahi Dehkordi, Universal Diagnostics d.o.o., Ljubljana, Slovenia

A032 FIT for red flag signs and symptoms of early onset colorectal cancer: low value or viable diagnostic tool? Daniel Sabater Minarim, University of California San Diego, La Jolla, CA, United States

A033 Community-Based Pilot Study of Colorectal Cancer Susceptibility and Cardiometabolic Risk in Young Hispanic Adults. Meng-Han Tsai, Augusta University, Augusta, GA, United States

A034 Model-free scoring system for risk prediction and early detection. Ying Yuan, University of Texas MD Anderson Cancer Center, Houston, TX, United States

A035 A complex clinical evolution: Mediastinal unicentric Castleman disease preceding paraneoplastic pemphigus and bronchiolitis obliterans. Chase V. West, Baylor College of Medicine, Houston, TX, United States

A036 Afferent loop syndrome in a young patient with extrahepatic cholangiocarcinoma: A challenging postoperative anatomy after complex hepatobiliary surgery. Humberto R. Nieves-Jiménez, Baylor College of Medicine/MD Anderson Cancer Center, Houston, TX, United States

Poster Session B

Thursday, December 11, 2025, 4:30-6:00 p.m.

B001 Implementation Science-Informed Development of a Comprehensive Early Onset Cancer Program: Provider Perspectives. Thejal Srikumar, Yale University School of Medicine, New Haven, CT, United States

B002 Addressing knowledge gaps in early-onset cancers: Radiological insights into oncogenic-immune dynamics of anaplastic Wilms tumors. Xiaoping Su, MD Anderson Cancer Center, Houston, TX, United States

B003 Risk Factors, Clinical and Molecular Characteristics of *de novo* Metastatic Early Onset Colorectal Cancer. Emma Schatoff, Memorial Sloan Kettering Cancer Center, New York, NY, United States

B004 The Cleveland Clinic's Young-Onset Colorectal Cancer Center and Registry: Integrating multidisciplinary clinical care and research infrastructure. Stephanie L. Schmit, Cleveland Clinic, Cleveland, OH, United States

B005 Comparative genomic analysis between early-onset and average-onset colorectal cancer patients at the Cleveland Clinic. Stephanie L. Schmit, Cleveland Clinic, Cleveland, OH, United States

B006 Early-onset colorectal cancer: 10-year review of histopathological trends in a tertiary hospital in Accra, Ghana. Barbara Adjei-Mensah, Korle Bu Teaching Hospital, Tema, Ghana

B007 Genetic and clinical profiles of early-onset prostate cancer in Puerto Rican men: A preliminary characterization. Gustavo Alayon-Rosario, Ponce Health Sciences University, Ponce, PA, Puerto Rico

B008 Neighborhood fast food, alcohol, and fruit/vegetable expenditure and early-onset colorectal cancer: A statewide spatio-ecological analysis in Alabama. R. Blake. Buchalter, University of Alabama at Birmingham, Birmingham, AL, United States

B009 Uncovering the Etiology of Early-Onset Gastric Cancer in Latinos Through Germline and Tumor Genomic Profiling. Luis G. Carvajal-Carmona, University of California, Davis, Davis, CA, United States

B010 Building a global research network focusing on etiology for early-onset colorectal cancer (EOCRC): findings from the Fight Colorectal Cancer 2025 Barcelona Think Tank. Andrea J. Dwyer, University of Colorado Cancer Center -Advisor to Fight Colorectal Cancer, Aurora, CO, United States

B011 Associations between county-level air pollutants and early-onset breast cancer incidence rates in the U.S. Anna Fischer, Michigan State University, East Lansing, MI, United States

B012 Sociodemographic and clinical determinants associated with early-onset breast cancer. Tara M. Friebe-Klingner, Rutgers Global Health Institute, New Brunswick, NJ, United States

B013 Epidemiology of early-onset gastrointestinal cancers in Nepal: A scoping review. Saroj GC, Kakani PHC, Kakani, Nepal

B014 Early-onset breast cancer and reproductive timing: results from the Mexican Teachers' Cohort. Liliana Gomez-Flores-Ramos, Secihti-National Institute of Public Health, Cuernavaca, Mexico

B015 Impact of sun sensitivity and ultraviolet radiation on the association between blistering sunburns and keratinocyte carcinoma. Belinda L. Gorsuch, National Cancer Institute, Rockville, MD, United States

B016 Survival differences after diagnosis of early-onset colorectal cancer by race/ethnicity and neighborhood-level socioeconomic status. Talar S. Habeshian, Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States

B017 Trends in early-onset colorectal, appendiceal, and anal tumour incidence by histological subtype in Australia from 1990 to 2020: A population-based time-series analysis. Mark Jenkins, The University of Melbourne, Parkville, Australia

B018 Early-onset ovarian cancer in U.S. veterans: A National Cancer Database study. Sanjana E. Kashyap, University of Illinois at Chicago, Chicago, IL, United States

B019 Lifestyle and reproductive factors and early-onset invasive epithelial ovarian cancer risk. Anita Koushik, McGill University, Montreal, QC, Canada

B020 Early-onset colorectal cancer mortality trends and birth cohort effect in Mexico, 1998-2023. Martin Lajous, Instituto Nacional de Salud Publica, Cuernavaca, Mexico

B021 Survival differences between early onset (< 50 years) and average onset (≥ 50 years) colorectal cancer among African Americans in metropolitan Detroit. Grace Lee, Georgetown University, Washington DC, United States

B022 Trends in the Cumulative Incidence of Second Primary Cancers Among Survivors of Early-Onset Cancer in the United States, 1975-2022. Sunyeop Lee, Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States

B023 Supplement And Medication Use in Early-Onset Colorectal Cancer: An Analysis of the Ohio Colorectal Cancer Prevention Initiative. Holli A. Loomans-Kropp, The Ohio State University, Columbus, OH, United States

B024 Feasibility of survey-based data collection in a diverse colorectal cancer cohort: Early-onset vs. average-onset. Citlalli Lopez, Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX, United States

B025 Universal Germline Testing in Young-Onset GI Malignancies: Expanding Access for Underserved Patients. Kaysia Ludford, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

B026 Pre-diagnostic disease and medication history in early-onset pancreatic cancer from large-scale registry and EHR data. Sif Ingibergsdóttir. Novitski, University of Copenhagen, Copenhagen, Denmark

B027 Early-Onset Head and Neck Cancer: Implications for Risk Stratification and Survival. Joab O. Odera, Duke University School of Medicine, Durham, NC, United States

B028 Co-occurring social determinants of endometrial cancer disparities in *All of Us*. Oyomoare Osazuwa-Peters, Duke University School of Medicine, Durham, NC, United States

B029 Clinical and Sociodemographic Associations Between Early-Onset and Late-Onset Colorectal Cancer in a U.S.–Mexico Border Population. Atharva Railkar, Texas Tech University Health Sciences Center, El Paso, El Paso, TX, United States

B030 Temporal Trends in the Incidence of Obesity-Associated Cancers in Puerto Rico, 2000–2022: Disproportionate Increases Among Younger Adults. Carola T. Sánchez-Díaz, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico

B031 Clinicopathologic features associated with metastatic early-onset gastric cancer.

Jessica Sheth Bhutada, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, United States

B032 Incidence of early onset colorectal, kidney, uterine, and pancreatic cancer by county-level obesity prevalence in the U.S., 2010-2022. Meredith Shiels, National Cancer Institute, Rockville, MD, United States

B033 A Comparative Study of Cervical Cancer Treatment Outcomes Between Reproductive-Aged and Post-Menopausal Women in a Tertiary Hospital in Bangladesh. Farzana Sultana, Institute of Science Tokyo, Japan, Tama, Japan

B034 Sex and Racial Disparities in Time to Treatment for Early-Onset Colorectal Cancer Across a Four-Level Rurality Classification in the United States. Meng-Han Tsai, Augusta University, Augusta, GA, United States

B035 Multilevel Insights into Obesity, Race/Ethnicity, and Survival in Early-Onset Colorectal Cancer in Georgia. Meng-Han Tsai, Augusta University, Augusta, SC, United States

B036 Non-steroidal anti-inflammatory drugs use and risk of colorectal cancer molecular subtypes: A systematic review and meta-analysis. Mary Jose. Urruchúa-Rodríguez, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany

B037 Early-Onset Cancer: A Focus on Pregnancy-Associated Cases. Nicole C. Loroña, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States

B038 Differences in metabolomic profiles predictive of fatigue in early-onset vs. later-onset colorectal cancer. Nicole C. Loroña, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States

Poster Session C

Friday, December 12, 2025, 5:00-6:30 p.m.

C001 Novel Sex-Specific Metabolic Phenotypes in Early Onset Colorectal Cancer. Oladimeji Aladelokun, Yale University, New Haven, CT, United States

C002 Early-onset colorectal cancer is characterized by transcriptional changes indicating increased epithelial-mesenchymal transition and metastatic potential. Ana C. Anderson, Gene Lay Institute of Immunology and Inflammation, Mass General Brigham, Harvard Medical School, Boston, MA, United States

C003 Neonatal Dried Blood Spot Metabolomics Reveals Signatures of Early-Onset Myeloproliferative Neoplasms. Domenica Berardi, Yale University, New Haven, CT, United States

C004 Colonic Tissue Renewal, Retinoic Acid Signaling, Early-onset CRC. Bruce Boman, Helen F. Graham Cancer Center & Research Institute, Newark, DE, United States

C005 *APC* Mutation-induced Retardation of Tissue Renewal is Fundamental to Colon Tumorigenesis. Bruce Boman, Helen F. Graham Cancer Center & Research Institute, Newark, DE, United States

C006 Association of high birth weight with risk of early-onset colorectal cancer. Chun R. Chao, Kaiser Permanente Southern California; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States

C007 Age-stratified insight into genomic alterations in colon adenocarcinoma via AACR GENIE v18.0. Johnathan D. DeBetta, Johns Hopkins University, Baltimore, MD, United States

C008 Characterizing factors associated with early onset breast cancer to inform tailored strategies for cancer risk assessment, screening, and treatment. Veda N. Giri, Yale Cancer Center, Yale School of Medicine, New Haven, CT, United States

C009 Distinct metabolic and genetic alterations in tumors from early-onset versus late-onset colorectal cancer. Caroline Johnson, Yale School of Public Health, New Haven, CT, United States

C010 Association of a germline KDM3C polymorphism with early cancer diagnosis. Zachary Kiss, Fox Chase Cancer Center, Philadelphia, PA, United States

C011 Distinct peripheral immune signatures in early-onset colorectal cancer reveal candidate biomarkers for risk stratification. Jose Perea, Hospital Vithas Arturo Soria, Madrid, Spain

C012 Transcriptional profiling of circulating immune cells from patients with early- and late-onset colorectal cancer reveals sex-specific differences. Jose Perea Garcia, Institute of Biomedical Research of Salamanca, Salamanca, Spain

C013 Spatial immune profiling of early- and late-onset colorectal cancer. Baohua Sun, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

C014 Unexplained familial early-onset colorectal cancer: Determining a shared etiology by tumor mutational signature profiling. Daniel D. Buchanan, University of Melbourne, Parkville, VIC, Australia

C015 Mutational signature profiling identifies a distinct subgroup of early-onset colorectal cancer associated with younger age at diagnosis, recent birth year, and specific genomic features. Daniel D. Buchanan, University of Melbourne, Parkville, VIC, Australia

C016 Exploring the exposome impact in early-onset colon and rectal cancer using methylation scores. Silvana C.E. Maas, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

C017 Exogenous carcinogenic exposures in early-onset pancreatic carcinogenesis: Insights from alcohol and tobacco-driven models. Nagaraj Nagathihalli, University of Miami School of Medicine, Miami, FL, United States

C018 Urinary Arsenic and Other Heavy Metals in Gallbladder Cancer Patients: A Pilot Study Correlating Exposure with Drinking Water and Assessing Carcinogenic Risk in Northeast India.

Christy Thomas, National Institute of Pharmaceutical Education and Research (NIPER),
 Guwahati, Kamrup, India

C019 Early-life penicillin blooms colibactin-positive Escherichia coli and drives DNA damage and tumorigenesis. Max R. Van Belkum, Vanderbilt University School of Medicine, Nashville, TN, United States

C020 Novel insights from the investigation of experimental mutational signatures in early-onset colorectal cancer and colonic polyps. Peter Georgeson, The University of Melbourne, Melbourne, VIC, Australia

C021 Characterizing the clinicopathological, genomic and spatial transcriptomic features of colibactin-induced colorectal cancers. Peter Georgeson, University of Melbourne, Parkville, VIC, Australia

C022 Multidimensional assessment of toxicities and survivorship among people with early-onset colorectal cancer – Results from the ColoCare Study. Jane C. Figueiredo, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, United States

C023 Studying early onset cancer: benefits and limitations of studies within the Military Health System. Celia Byrne, Uniformed Services University, Bethesda, MD, United States

C024 Somatic mutations in early-onset colorectal cancer: insights from a U.S. Hispanic cohort. Maria Gonzalez-Pons, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico

C025 Endometrial cancer mutation patterns by age with possible increased TP53 and decreased PTEN mutations in patients 50+ years old. Camille McCallister, Penn Medicine, Philadelphia, PA, United States

C026 Disparate response to chemoradiation in early onset vs late onset rectal cancer.

Joshua E. Meyer, Fox Chase Cancer Center, Philadelphia, PA, United States

C027 Association of Binge Drinking with Early-Onset Colorectal Cancer: A Comparison to Late-Onset Cancers. Electra D. Paskett, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, OH, United States

C028 GSK3 β : a therapeutic target in KRAS mutant pancreatic cancers. Mir Owais Ayaz, CSIR IIIM Jammu, Jammu, India

C029 Tumor-adjacent visceral adipose tissue displays an altered transcriptomic landscape in early-onset colorectal cancer patients: Results from the ColoCare Study. Victoria M. Bandera, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, United States

C030 Effect of palmitic acid exposure in normal colon organoids derived from young versus older individuals. Casidhe-Nicole R. Bethancourt, Columbia University, New York, NY, United States

C031 Evexomostat (SDX-7320), a methionine aminopeptidase type 2 (METAP2) inhibitor, inhibits obesity-accelerated tumor growth and stimulates weight loss in obese mice. Peter Cornelius, SynDevRx, Inc., Cambridge, MA, United States

C032 Visceral fat area and age-related differences in visceral adipose tissue gene expression: implications for early-onset colorectal cancer. Patricia A. Erickson, Huntsman Cancer Institute, Salt Lake City, UT, United States

C033 Transcriptomic and pathway analyses patterns in early-onset and late-onset microsatellite stable colorectal cancer: Results from the ORIEN Network. Sheetal Hardikar, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States

C034 Obesity-Linked Leptin Signaling Promotes Immune Checkpoint Expression and Tumor Cell Survival. Iqra Kousar, China Medical University, Taichung, TN, Taiwan (Greater China)

C035 Altered developmental programming of intestinal stem cells in a maternal obesogenic environment as a risk factor for EO-CRC. Miyeko D. Mana, Arizona State University, Tempe, AZ, United States

C036 The Neurological and Immunological Interplay in Cancer Progression and Treatment Response. Jordan A. Steward, Arizona State University, Chicago, IL, United States

C037 Fructose-induced *Akkermansia muciniphila* promotes colorectal cancer progression through N-acetylneuraminic acid-mediated macrophage reprogramming. Yingzhao Wang, NYU Grossman School of Medicine, New York, NY, United States